Answers are grounded in this paper and cite their sources.
Normothermic machine perfusion (NMP) has been introduced into transplantation to improve the outcomes of kidneys from marginal donors. This review focuses on the application of NMP detailing the clinical evidence and examining the underlying mechanistic actions. It then explores the evidence for more prolonged periods of NMP and modifications to the protocols. There are only a handful of clinical studies reporting the outcomes of NMP on early renal allograft function. All of the studies used an end period of NMP approach in conjunction with hypothermic preservation techniques. All validated the safety and feasibility of NMP and several reported improved early graft function. Although NMP restores oxidative phosphorylation to support active metabolism and replenish cellular adenosine triphosphate (ATP), inflammatory and immune processes are also activated. This is in response to the period of ischaemia prior to NMP but may also be exacerbated by the perfusion conditions. Removing the inflammatory mediators during NMP, altering conditions or extending the NMP time to minimise ischaemic injury may be beneficial for future application. NMP is a promising new technology in kidney transplantation. Ongoing clinical studies and further development of NMP will determine the benefit of this technology in the coming years.
No takes yet. Share an insight, caveat, or question.
Hosgood et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: